Dr. Jamshidi is an ophthalmologist specializing in vitreoretinal diseases as well as posterior segment tumors. He completed a combined MD/PhD degree at the University of British Columbia where his thesis was focused on the genomics of rare cancers. This was followed by post-doctoral studies in ocular genomics at Harvard Medical School and ophthalmology residency at the Dean McGee Eye Institute. Dr. Jamshidi then trained in vitreoretinal surgery followed by advanced training in posterior segment oncology at the University of Iowa.
- Advanced Training in Posterior Segment Tumors, University of Iowa
- Vitreoretinal Surgery Fellowship, University of Iowa
- Ophthalmology Residency, Dean McGee Eye Institute
- Post-doctoral Research Fellowship, Harvard Medical School
- MD/PhD, University of British Columbia Faculty of Medicine
Education & Training
Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature. Jamshidi F, Lozano L, Tucker B, Andorf J, Sohn E, Stone E, Groves A, Zakharia Y, Boldt HC, Binkley E. Ocul Oncol Pathol. 2024 Sep;10(3):154-161. doi: 10.1159/000539434. Epub 2024 May 24.
Management of choroidal/ciliary body metastasis in the era of targeted cancer therapy. Evbuomwan MO, Bhuyan R, Uzomah UA, Jamshidi F, Anderson C, Boldt HC, Binkley E. Front Oncol. 2024 Dec 20;14:1516783. doi: 10.3389/fonc.2024.1516783. eCollection 2024.
Vitreoretinal Procedures in Patients with Inherited Retinal Disease. Fenner BJ, Jamshidi F, Bhuyan R, Fortenbach CR, Jin HD, Boyce TM, Binkley EM, Han IC, Sohn EH, Boldt HC, Folk JC, Russell SR, Stone EM, Russell JF. Ophthalmol Retina. 2024 Mar;8(3):307-309. doi: 10.1016/j.oret.2023.10.020. Epub 2023 Nov 2.
Contribution of noncoding pathogenic variants to RPGRIP1-mediated inherited retinal degeneration. Jamshidi F, Place EM, Mehrotra S, Navarro-Gomez D, Maher M, Branham KE, Valkanas E, Cherry TJ, Lek M, MacArthur D, Pierce EA, Bujakowska KM. Genet Med. 2019 Mar;21(3):694-704. doi: 10.1038/s41436-018-0104-7. Epub 2018 Aug 3.
Copy-number variation contributes 9% of pathogenicity in the inherited retinal degenerations. Zampaglione E, Kinde B, Place EM, Navarro-Gomez D, Maher M, Jamshidi F, Nassiri S, Mazzone JA, Finn C, Schlegel D, Comander J, Pierce EA, Bujakowska KM. Genet Med. 2020 Jun;22(6):1079-1087. doi: 10.1038/s41436-020-0759-8. Epub 2020 Feb 10.
My primary research interest is in understanding the pathophysiology behind the variability in clinical behavior of eye tumors. While some tumors appear to have similar genomic drivers, the differences in the aggressiveness of their presentation, for instance in retinal hemangioblastomas of Von Hippel-Lindau syndrome, or their micro-metastatic behavior, such as the immune evasion of choroidal melanomas, remain enigmatic. Understanding the mechanisms behind these differences can lead to improved diagnostics and treatments. Additionally, understanding the intricacies of choroidal physiology and regulation via novel imaging modalities and experimental models is another area of interest. This would help improve our understanding of a wide range of chorioretinal diseases, in addition to choroidal tumors.